PureTech, Roche to use exosomes for oral drug delivery

PureTech Health plc (LSE:PRTC) partnered with Roche (SIX:ROG; OTCQX:RHHBY) to develop PureTech's milk-derived exosome platform to orally deliver Roche's antisense oligonucleotides.

PureTech

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE